REMICADEÂ Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis

HORSHAM Pa. Sept. 23 2011 PRNewswire Janssen Biotech Inc. announced today that the U.S. Food and Drug Administration FDA has approved REMICADE&174; infliximab for the treatment of moderately to severely active ulcerative colitis UC in pediatric patien...